We are live on ! Find out more

Ascendis Pharma A/S

ASND

Market cap $16.6B

253.00 USD

+3.45

1.38%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

253.00

0.00

0%

1 day

1.38%

5 days

4.55%

1 month

10.93%

3 months

0.38%

6 months

14.85%

Year to date

18.62%

1 year

22.99%

5 years

66.88%

10 years

1,199.44%

About: Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Employees: 1,189

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20.8%

Neutral 75%

Negative 4.2%

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

COPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon® PTH (palopegteriparatide) for up to 5 years in the Company's Phase 2 PaTH Forward and Phase 3 PaTHway trials. Results from the pooled analysis were shared in a poster presented by nephrologist Elvira Gosmanova, M.D.

TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma's Marketing Authorisation Application (MAA) is expected during Q4 2026.

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Zacks Investment Research

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon® PTH (palopegteriparatide) over a 5-year period.

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Ascendis Pharma: Back To Full Independence

Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and pipeline disappointments. Despite pipeline contraction, ASND's approved products—Skytrofa, Yorvipath, and Yuviwel—show robust growth, and Yorvipath net sales should exceed $1.1 billion this year. Yuviwel's strong U.S. launch and favorable BioMarin settlement provide freedom to operate.

Ascendis Pharma: Back To Full Independence

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

Ascendis Pharma A/S (NASDAQ:ASND) shares are trading lower on Tuesday as investors digest news that the company will regain rights to certain TransCon technology-based programs and a share buyback.

Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Ascendis Announces Planned $400 Million Share Repurchase Program

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company's ordinary shares (the Share Repurchase Program).

Ascendis Announces Planned $400 Million Share Repurchase Program

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

See News Rankings

Price charts implemented using Lightweight Charts™